Risankizumab-rzaa topical and Stelara

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious bacterial, fungal, and viral infections have been observed during clinical trials with ustekinumab, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids. MANAGEMENT: Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. References "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.

MONITOR: The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious bacterial, fungal, and viral infections have been observed during clinical trials with ustekinumab, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.

MANAGEMENT: Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.

Risankizumab-rzaa topical

Generic Name: risankizumab

Brand name: Skyrizi

Synonyms: Risankizumab

What is Risankizumab-rzaa topical?

Stelara

Generic Name: ustekinumab

Brand name: Stelara, Stelara PFS

Synonyms: n.a.

What is Stelara?